The latest antibody treatment for Alzheimer's disease may prompt the industry toward the use of biomarkers—rather than traditional cognitive and functional testing—for diagnosis and staging. Will the new drug make a meaningful difference in patients' lives despite its risks and hefty price tag?
No takes yet. Share an insight, caveat, or question.
Linda M. Richmond (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: